Literature DB >> 14675115

Heparin-releasable TFPI is not depleted after repeated injections of tinzaparin at therapeutic dose for up to 30 days.

I Gouin-Thibault, E Pautas, F Depasse, J P Andreux, V Siguret.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14675115     DOI： 10.1111/j.1538-7836.2003.0543k.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  3 in total

Review 1.  Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis.

Authors:  Sheridan M Hoy; Lesley J Scott; Greg L Plosker
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

Review 2.  Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.

Authors:  Susan M Cheer; Christopher J Dunn; Rachel Foster
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses.

Authors:  Marina Amerali; Marianna Politou
Journal:  Eur J Clin Pharmacol       Date:  2022-07-23       Impact factor: 3.064
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.